DAHUA-TECHNOLOGY
22.11.2022 13:46:43 CET | Business Wire | Press release
Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has been accelerating the innovation and exploration of Full-color Technology. Featuring TiOC, Panoramic, Zoom and 4K, the new generation of Dahua full-color series provides a wide range of low-light solutions that integrate different intelligent technologies to solve pain points in various scenarios, allowing installers and end users to choose the ideal solution that best suits their needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005376/en/
Inadequate availability of light is one of the major challenges of every monitoring system. Images taken under such lighting condition are often not clear, have detail loss, and even contain noise, making it difficult to detect or trace back targets in case of an event. The Dahua Full-color cameras were developed to address these demanding monitoring challenges. With remarkable offerings such as dual lens, vari-focal lens, 4K resolution, and AI features, this technology offers a wide-range of products and solutions that can effectively solve the arduous monitoring pain points of end-users and provide clear and vivid images of the monitored scene 24/7. (Photo: Business Wire)
Full-color + TiOC: effective deterrent against intruders
The Dahua TiOC (three-in-one camera) integrates Smart Dual Illuminators, Active Deterrence, and AI to offer a pro-active monitoring solution that can effectively warn off intruders. The combination of Dahua’s industry-leading full-color technology with powerful AI functions and real-time Active Deterrence warnings makes it suitable for places that require 24/7 security, such as villas, shops, warehouses, etc., helping to reduce false alarm rates, improve target search efficiency, generally optimize system operation, and reduce costs.
Full-color + Panoramic: the whole scene in vivid color
The Dahua Full-color Dual Lens 180° Panoramic PTZ & IPC are equipped with dual sensors that deliver a 180-degree field of view. It adopts the Dahua pixel-level seamless fusion algorithm to splice images into horizontal 180° monitoring scene, providing users with brilliant full-color and panoramic images. Featuring wide-area coverage, it is an excellent alternative to daunting installation of multiple cameras just to cover a large scene. Thanks to Full-color Technology, the intelligent panoramic camera can provide clear color images even at night, which is essential for 24/7 continuous monitoring in large application scenarios such as squares, hallways, and parking lots.
Full-color + ZOOM: vari-focal zoom in with vivid color
The Dahua Full-color Vari-focal Camera boasts approx. 5x optical zoom capability and auto-focus function. These cameras provide clear monitoring scene details even after zooming in, capture vivid color images in dark environments, and also allow users to directly adjust the camera’s focus according to the actual scene, which is convenient and time-saving.
Full-color + 4K: Realistic 4K UHD image quality
The Dahua Full-color 4K Camera delivers enhanced color images and video footages 24/7. It adopts 1/1.2” image sensor (currently Dahua's best low-light IPC sensor) that provides 110% pixel size increase compared to common 8MP sensor. Combined with a F1.0 large aperture, more available light can be captured to provide clear and vivid images, which is conductive to accurate video analysis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005376/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom